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Abstract
Background: The personalization of cancer treatments implies the reconsideration of a one-size-fits-all paradigm.
This move has spawned increased use of next generation sequencing to understand mutations and copy number
aberrations in cancer cells. Initial personalization successes have been primarily driven by drugs targeting one
patient-specific oncogene (e.g., Gleevec, Xalkori, Herceptin). Unfortunately, most cancers include a multitude of
aberrations, and the overall impact on cancer signaling and metabolic networks cannot be easily nullified by a
single drug.
Methods: We used a novel predictive simulation approach to create an avatar of patient cancer cells using point
mutations and copy number aberration data. Simulation avatars of myeloma patients were functionally screened
using various molecularly targeted drugs both individually and in combination to identify drugs that are efficacious
and synergistic. Repurposing of drugs that are FDA-approved or under clinical study with validated clinical safety
and pharmacokinetic data can provide a rapid translational path to the clinic. High-risk multiple myeloma patients
were modeled, and the simulation predictions were assessed ex vivo using patient cells.
Results: Here, we present an approach to address the key challenge of interpreting patient profiling genomic
signatures into actionable clinical insights to make the personalization of cancer therapy a practical reality. Through
the rational design of personalized treatments, our approach also targets multiple patient-relevant pathways to
address the emergence of single therapy resistance. Our predictive platform identified drug regimens for four
high-risk multiple myeloma patients. The predicted regimes were found to be effective in ex vivo analyses using
patient cells.
Conclusions: These multiple validations confirm this approach and methodology for the use of big data to create
personalized therapeutics using predictive simulation approaches.
Keywords: Multiple myeloma, Rational drug design, Personalized therapy
Background
Multiple myeloma (MM) is a blood disorder that impairs
and suppresses the immune system [1,2]. MM is the
second most common hematological malignancy and is
characterized by the infiltration, expansion and survival
of malignant plasma cells in the bone marrow that
typically become resistant to all chemotherapies. The
development of drug resistance is a significant clinical
obstacle in the treatment of MM. High levels of intra-
patient heterogeneity in malignant cells in terms of
genetic aberrations and characteristics as well as inter-
actions with the bone marrow microenvironment are
the major determinants of MM resistance mechanisms
[3-7]. Despite a similar manifestation of disease end-
points, inter-patient heterogeneity in cellular profiles
results in a wide variety of responses to similar drugs
among patients. In addition, the lack of a common re-
current mutation provides further reason to explore
this disease on a personalized basis. This presents an
opportunity to develop and design personalized therap-
ies based on the specific set of cellular profiles and
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microenvironment influences that can also differ bet-
ween patients.
The well-defined standard of care treatments cur-
rently used for MM include proteasome inhibitors, such
as bortezomib and carfilzomib, and immunomodulator
(IMiD) drugs, including thalidomide, linalidomide and
pomalidomide. Conventional cytotoxic chemotherapy
drugs, such as melphalan, cyclophosphamide, and do-
xorubicin, are also used in MM therapy. Stem cell trans-
plantation is another treatment option available for MM
[3]. MM patients typically initially respond to the primary
standard of care, and then a few develop resistance or sim-
ply do not respond to the existing and available standards
of treatment. This lack of response could be attributed to
the presence of CD138+ and CD138− clones in patients,
which differentially respond to drug therapies [4]. Over
time, the sensitive clone is eliminated, and the resistant
clone subsequently dominates, resulting in disease recur-
rence. Additionally, factors and conditions in the bone
marrow microenvironment, including increased levels
of cytokines and chemokines (IL6 and CCL5), stem cell
signaling mediated by WNT and NOTCH, and hypoxic
microenvironments, also contribute to drug resistance
[8-13].
In this study, we used predictive simulation modeling
of cancer physiology to design and shortlist therapies
predicted to overcome MM resistance. Cancer physi-
ology simulation technology (Cellworks Group, San Jose,
CA, USA) can be used to conduct high-throughput stu-
dies to assess complex biological mechanisms resulting
from drug treatment [14-18]. Specifically, the system
predicts mechanisms using drug combinations that syn-
ergistically interact to reduce viability, proliferation and
other biologically relevant endpoints. The predictive
simulation technology comprehensively incorporates in-
tegrated networks of signaling and metabolic pathways
that underlie all cancer phenotypes [19]. A high-level
schematic of the network circuitry of key signaling path-
ways, message transduction cascades and transcription
factor-mediated regulation of gene expression along with
cellular processes incorporated into the plasma cell
simulation platform is presented in Figure 1A. A list of
abbreviations that appear in the pathway schematic can
be found in Additional file 1. Using genomic profiling in-
formation from patient tumors as inputs into the system,
a patient simulation avatar is created. This predictive
platform was then used to test a library of molecularly tar-
geted drugs on the patient simulation avatar. Drug agents
were combined at different dose ratios via simulation-
based studies, resulting in analyses of the effects of a large
number of drug combinations on functional phenotypes,
including proliferation, viability, angiogenesis and bio-
marker expression. The shortlisted novel combinations
were experimentally validated ex vivo in corresponding
patient cells at the phenotype and biomarker levels.
Our predictions were confirmed by our experimental
results.
The predictive simulation approach differs from other
pathway modeling approaches. Unlike a static network,
big data mining or informatics approach, this approach
enables novel drug simulations and predictions prospect-
ively validated using clinical and biomarker endpoints.
The integrated cancer physiology network that covers all
disease phenotypes in the simulation model are aggre-
gated through manual scientific review one reaction at a
time to maintain a high quality of input information and
address issues of prevalent contradictory datasets. In
addition, the network is continuously enhanced with
information from new research. The semiconductor en-
gineering methodology and infrastructure makes feasible
a large quantum of simulation dose response studies to
shortlist specific therapeutic and biomarker assets from
millions of studies.
Methods
Collection of samples and growing patient cell line
Samples were obtained after informed consent was pro-
vided by patients in accordance with the Human Subjects
Protection Committee and the Declaration of Helsinki.
Human experimentation guidelines of the United States
Department of Health and Human Services and those of
New York University were followed. This study was ap-
proved by the New York University Institutional Review
Board (protocol number 06-523) and the Washington
University School of Medicine Institutional Review Board
(HRPO 201102270). All of the patients selected for this
study failed all the existing approved standard of care
treatments for myeloma. Bone marrow aspirates were col-
lected in heparinized tubes and then diluted 1:1 with
Leibovitz L-15 medium (Life Technologies) supplemen-
ted with fetal bovine serum, interleukin [IL]-6 (IL-6),
vascular endothelial growth factor (VEGF), insulin-like
growth factor-1 (IGF-1).The mononuclear cell fraction
was enriched by Ficoll-Hypaque (Pharmacia) density
gradient sedimentation at 600 g for 20 min and washed
twice in L-15/fetal bovine serum media as previously
described [20]. For sample 5, CD138+ plasma cell isola-
tion was performed by FACS analysis. Cells were then
propagated in RPMI media supplemented with IL-6,
VEGF and IGF-1. Cells were co-cultured with the sup-
port of M210B4 stromal cells (Cases 1-3) or patient
stromal cells (Case 4) [21].
Genomic signature of patient myeloma cells
Results from genome-wide assays that report deviations
from the genome of a non-cancerous cell were used to
provide information about the patient’s genomic signature.
We used data from aCGH (array comparative genomic
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hybridization) and cytogenetic profiling to create the si-
mulation avatar of MM patients. aCGH is a molecular
cytogenetic method for analyzing copy number variations
(CNV) relative to DNA ploidy levels in a test sample com-
pared with a reference sample, such as malignant tumor
cells compared with normal cells of the same patient.
aCGH can detect aneuploidies, including deletions, dupli-
cations, and/or amplifications, of any locus represented on
an array, thus providing a snapshot of the patient’s tumor
genomic signature. CD138- cells from the bone marrow
sample were used as the non-cancerous reference for
each patient. Cytogenetic profiling by spectral karyotyping
(SKY) reports chromosomal aberrations, including loss/
gain of complete chromosomes or specific chromoso-
mal regions resulting in monosomy/trisomy of the genes
in the affected region. In addition to deletions and du-
plications, other abnormalities that are reported include
derivative chromosomes, isochromosomes, and translo-
cations. Both aCGH/SKY methods can be further sub-
stantiated by FISH (fluorescent in situ hybridization)
using marker genes in the affected chromosomal regions
[22-25]. Additionally, whole genome sequencing (WGS)
Figure 1 Predictive platform design and study workflow. (A) Schematic representing the crosstalk between various pathways in the plasma
cell simulation platform. An oversimplified graphical representation of the signaling components, including key kinases, transcription factors and
genes, that underlie various cancer phenotypes incorporated in the network is presented. The schematic also highlights cellular processes that
are modeled, including epigenetic regulation, tumor metabolism, oxidative stress, protein homeostasis (proteasome and autophagy), cell cycle
machinery and DNA repair pathways. The crosstalk between all these pathways represents our control non-triggered simulation platform that
can be transitioned into the respective disease state by triggering the mutations and aberrations reported for a profile. (B) Description of
process for designing personalized therapy: The process flow for the N = 1 personalized therapy design as described in the Methods section is
presented. A bone marrow sample from the patient tumor is profiled, and the tumor signature consisting of CNV, mutations and other
relevant data is input into the simulation model to create the simulation patient avatar. A drug library is tested on this patient avatar to
identify drugs and therapies predicted to be sensitive or resistant in the particular profile. This information can be validated ex vivo via
non-clinical validation or clinically translated by either connecting to a specific ongoing clinical study or the personalized N = 1 option for
that particular patient.
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or exome sequencing data can report CNV as well as
point mutations that provide the genomic signature of the
patient tumor and enable the creation of the patient simu-
lation avatar.
Creation of patient simulation avatars
The input genomic data from aCGH/SKY/WGS were
used to create a list of all numerical and/or structural
aberrations in the patient’s genome. The genes found on
the loci of these affected regions of the chromosome
are extracted from the human reference genome at
ENSEMBL. The complete list of genes is matched with
the Cellworks MM model to identify genes that are rep-
resented in the model. All genes that have coverage in
the model form the trigger file that is used to create the
patient’s simulation avatar as previously reported [19].
The genes reported to have gain in copy number are
overexpressed, whereas genes with a loss in copy num-
ber are knocked-down.
Simulation protocol
The dynamic cancer model is simulated for 50,000 sec-
onds until the system reaches a homeostatic steady state,
thus being initialized to a control state aligned to normal
plasma cell physiology that is non-tumorigenic. This
non-transformed plasma cell is triggered to transition
into a neoplastic state by introducing the patient trigger
file. The model is further simulated for 50,000 to 100,000
seconds after the introduction of the triggers that modu-
late the functional levels of intracellular molecules to align
the system to the network dynamics of the patient’s tumor
and to achieve a disease steady state. It is important to
note that the time to achieve steady state of the disease
network varies based on the complexity of the profile
definition.
Designing individualized therapy
The creation and simulation of the patient simulation
avatar is followed by high throughput data and network
analysis of the system to provide insight into the do-
minant pathways and signaling loops in the particular
patient profile. The patient simulation network is not
dominated by one gene mutation or perturbation with a
significant phenotypic impact, rather the cumulative
effects of the multitude of chromosomal aberrations de-
rived from the genomic datasets that shift the dynamics
of the signaling network towards the disease phenotypes
of enhanced proliferation, increased viability and re-
duced apoptosis. Each patient profile is unique with re-
gard to the set of aberrations present, thereby resulting
in a significantly unique network configuration. We also
model and simulate different clones within a patient
sample with slightly different genomic aberrations to in-
corporate disease heterogeneity. The key characteristics
of the patient simulation avatar are represented as a net-
work schematic, including the list of tumor suppressor
and tumor promoter genes derived from the reported
aberrations to highlight the key pathways and markers
that are dominant in the particular profile.
Once the patient simulation avatar is created, a library
of drug agents is simulated on the profile for an add-
itional 50,000 to 100,000 seconds. The drug library is
tested at physiologically achievable concentrations that
will manipulate the target moderately by 50-60%. The
drug concentration used in the simulation study is
assumed to represent a physiological concentration after
drug absorption, distribution, transport, and metabolism.
High throughput studies of the drug library are per-
formed on the patient clones at physiological concentra-
tions, and those doses exhibiting a greater than 30%
efficacy on the disease endpoints of reduction in tumor
relative growth index are shortlisted for further analysis.
The tumor relative growth index is a complex predictive
phenotype index that includes weighted functions of
biomarkers impacting proliferation, survival, and apop-
tosis, including cell cycle checkpoint CDK-cyclin com-
plexes; pro-survival markers, such as BCL2, MCL1, and
BIRC3; and pro-apoptotic markers, such as caspases,
Puma, and cleaved PARP1.
Given that small molecule inhibitors are primarily
used in the study, the optimal manipulation of the target
achievable at physiological drug doses is assumed to be
approximately 50% with the exception of biologic drugs,
such as antibodies, where the target inhibition would be
greater than 90%. The effect of the target manipulation
is assessed across a dose range, and the dose used in the
combination regimen was chosen based on the percent-
age of target inhibition or the concentration that results
a specific inhibition (inhibitory concentration (IC)20 or
IC30) or relative growth.
The mechanisms of action of the shortlisted drugs are
analyzed in terms of the patient network dominance,
and those individual or combination agents that align
with reducing the key biomarkers and converging nodes
in the network are selected for experimental ex vivo
validation using patient tumor cells. For combination
therapy, combinations resulting in a synergistic reduc-
tion of the biomarkers and endpoints are selected such
that the effect is not dominated by one agent. This al-
lows very low concentrations of the drug agents (IC20)
to be combined, thereby achieving a greater than IC50
efficacy.
Figure 1B summarizes the process flow for the N = 1
personalized therapy design as described above. Bone
marrow samples from the patient are profiled, and the
tumor signature comprising of CNV, mutations and
other relevant data are input into the simulation model
to create the simulation patient avatar. A drug library is
Doudican et al. Journal of Translational Medicine  (2015) 13:43 Page 4 of 14
tested on this patient avatar to identify the drugs that
would be sensitive or resistant in the particular profile.
This information is validated ex vivo for non-clinical val-
idation and also translated clinically by either connecting
to a specific ongoing clinical study or a personalized
N = 1 option for that particular patient.
Ex vivo validations use a drug concentration range in-
dividually based on drug affinity information available
from existing studies. From this dose response study,
the IC20 relative growth concentration is determined
for each drug in the combination. This concentration is
used to assess the efficacy of the drug combination.
Given that most of the drugs in the library are either
approved or in clinical development, ex vivo concentra-
tions are based on the approved or tested doses. Regard-
ing in vivo dosing, we would suggest using a moderately
effective dose of the drug and then escalating to the
maximal dose tolerable to the patient to obtain maximal
benefits.
Cell proliferation assays
For cell proliferation studies, 5,000 cells per well were
plated in 96-well culture plates. After overnight incuba-
tion, the cells were treated with indicated concentrations
of drug agents alone or in combination. Following a 48
hour incubation period, cellular proliferation was as-
sessed using a tetrazolium dye reduction assay (CellTiter
96 Aqueous Non-Radioactive Cell Proliferation Assay;
Promega, Madison, WI, USA) according to the manufac-
turer’s instructions. Absorbance was recorded on a mi-
croplate reader at 495 nm. Cellular proliferation was
expressed as a percentage of vehicle-treated cells, which
was defined as 100% viable.
Western blotting
For the detection of various proteins, treated cells were
lysed in lysis buffer (20 mM Tris, pH 7.4; 250 mM NaCl;
2 mM EDTA, pH 8.0; 0.1% TritonX-100; 0.01 mg/ml
aprotinin; 0.005 mg/ml leupeptin; 0.4 mM PMSF; 4 mM
NaVO4). Lysates were centrifuged at 14,000 rpm for
10 min to remove insoluble material and resolved on
a 7.5% SDS gel. After electrophoresis, the proteins
were electrotransferred to a nitrocellulose membrane,
blocked with 5% non-fat milk, and probed with anti-
cleaved PARP, Bcl2, AKT, phospho-AKT and NFκβ
antibodies (1:1000 dilution; Cell Signaling Technology,
Danvers, MA, USA) overnight at 4°C. An anti-β-actin
antibody (Sigma, St. Louis, MO, USA) was used as a
loading control. The blot was washed, exposed to
HRP-conjugated secondary antibodies (Cell Signaling
Technology, Danvers, MA, USA) for 1 hour, and ex-
amined by chemiluminescence (ECL; GE Healthcare,
Little Chalfont, Buckinghamshire, UK).
Results and discussion
Here, we present 4 case studies wherein personalized
therapies were designed for different MM patient profiles
that were then validated ex vivo using patient cells.
Case study 1
a. Patient genomic characteristics and creation of
patient simulation avatar
FISH studies revealed loss of signals of chromosome
13 as well as a reported loss of chromosome
17p13.1, which corresponds to loss of the P53 gene.
The genes present on the chromosome 13 were
mapped, and 19 genes out of a total of 875 present
in the Cellworks simulation model were perturbed
(knock-down) along with a deletion of the P53 gene;
these genes were used to create the patient
simulation avatar.
b. Design of individualized therapy
Upon analysis of the patient characteristics, this
profile with chromosome 13 monosomy and P53
deletion exhibited increased BCL2 levels and
reduced PTEN and IGFBP3 levels, which are
downstream of P53. In addition, a consequential
increase in AKT was noted. Our analyses predicted
a combination of BEZ235 (PI3K/mTOR inhibitor)
and ABT-199 (BCL2 mimetic) for a synergistic
reduction in the patient’s primary cell viability and
proliferation phenotypes. The combination therapy
was predicted to reduce key biomarkers, such as
AKT and BCL2, and impact the downstream
activation of pro-apoptotic markers, such as PARP1
and caspases.
c. Ex vivo validation
Given the personalized therapy prediction for MM
patient 1, the inhibition of the PI3K/mTOR axis
along with BCL2 was predicted to cause a
synergistic reduction in cell growth and viability, and
the effect is predicted to be significantly increased
compared with the individual drugs. These
predictive results were prospectively validated in
patient cells ex vivo, and a synergistic reduction in
cellular proliferation was observed experimentally
(Figure 2A and B). ABT-199 (2.5 μM) only reduced
proliferation by approximately 15%, whereas
5 μM BEZ235 reduced proliferation by 25%. In
combination at the same concentrations, the
reduction in cellular proliferation is synergistic with
a 60% reduction (Figure 2B). The phosphorylated
AKT biomarker exhibited enhanced growth
reduction with the PI3K/mTOR inhibitor BEZ2355,
and the same trend was observed upon combination
treatment (Figure 2D). The reduction in BCL2
expression was not greater with the BCL2 mimetic
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since the agent only competes with BCL2 for the
sequestration of the pro-apoptotic proteins. A
reduction in BCL2 expression could potentially
occur with NFkβ inhibition via reduction in
phosphorylated AKT (Figure 2C and D). A
synergistic increase in the pro-apoptotic biomarker
cleaved PARP1 was observed with the combination,
which correlated with the predictive trend for
PARP1 (Figure 2C and D). Due to reduction of the
dominant AKT pathway and BCL2 activity with the
two inhibitors, there is a convergence downstream
in the activation of apoptosis from these two different
pathways as indicated by the increase in PARP1.
d. Discussion
The patient-specific therapeutic simulation model
was conceptually deduced using distinctive
information from tumor signature as presented in
Figure 3. The patient reported with chromosome 13
monosomy that included heterozygous deletion of
the tumor suppressor genes RB1 and FOXO1 and
homozygous deletion of the P53 gene, thereby
presenting with high levels of BCL2, reduced PTEN
and IGFBP3 levels, and a consequential increase in
AKT levels. Inhibiting the PI3K/mTOR axis along
with a BCL2 mimetic resulted in a reduction of cell
proliferation and apoptosis biomarkers (AKT and
BCL2). The combination synergistically reduced
cell viability and proliferation and demonstrated
convergence at increased apoptotic biomarkers,
such as increased cleaved PARP1.
Case study 2
a. Patient genomic characteristics and creation of
patient simulation avatar
The aCGH and FISH analysis of the bone marrow
sample included losses in chromosomes X and 9 as
well as a chromosome 11:14 translocation that is a
Figure 2 MM patient 1 predictive vs. experimental results. Predictive (A) vs. experimental (B) results regarding the effect of ABT199 and
BEZ235 alone and in combination on cell proliferation in MM patient 1. Predictive (C) vs. experimental (D) results regarding the effect of ABT199
and BEZ235 alone and in combination on the biomarkers cleaved PARP1, BCL2 and AKT1.
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commonly reported in MM. This translocation
results in increased CCND1 expression. The
genomic aberrations reported included knockdown
of tumor suppressors RXRA, TGFBR1, TJP2 and
TSC1.
b. Design of individualized therapy
The simulation avatar of this patient profile revealed
increased mTOR signaling. TSC1 negatively
regulates mTOR1 pathway, and its deletion in the
patient’s genomic profile is predicted to cause
aberrant activation of mTOR1 and the pathway’s
downstream targets. A significant increase in the
proliferation endpoint is attributed to amplification
of cyclin D1 expression, increased activation of AP1
and NFkβ due to reduced RXRA and TJP2
expression and a reduction in cell cycle inhibitors
that are regulated by TGFb-mediated SMAD
signaling. Modeling predicted a combination of the
mTOR1 inhibitor sirolimus and the ERK inhibitor
trametinib to be efficacious for this profile
(Figure 4A).
c. Ex vivo validation
Sirolimus and trametinib were assessed individually
and in combination ex vivo on the patient cells.
Sirolimus (5 μM) exhibited a 10% decrease in
cellular proliferation, whereas 5 μM trametinib
caused an approximate 20% decrease. Combination
of the two drugs at the same concentration caused a
35% decrease in cellular proliferation, thus confirming
the prediction (Figure 4B and C). In addition, the
combination increases CDKN1A expression and
reduces cyclin D1 expression (Figure 4D).
d. Discussion
As demonstrated in the signaling network of the key
characteristics of the patient cancer cells illustrated
in Figure 4A, sirolimus inhibits the aberrantly
activated mTOR1 signaling due to TSC1 knockdown,
whereas trametinib significantly impacts AP1
activation via ERK inhibition. These effects
converge by reducing the amplified cyclin D1
and other key proliferative genes.
Case study 3
a. Patient genomic characteristics and creation of
patient simulation avatar
A deletion of chromosome 7 from region q22 to
q36, Del(7)(q22q36) that contained the CAV1,
Figure 3 MM patient 1 profile schematic. The key signaling pathways and crosstalk relevant for MM patient 1 are presented. The profile
includes chromosome 13 monosomy, loss of chromosome 17p13.1, heterozygous deletions of tumor suppressors RB1 and FOXO1 and a
homozygous deletion of P53. Genes presented in green exhibit reduced expression. This profile displayed high AKT activation due to reduced
PTEN and IGFBP3 expression, which are downstream of P53. Also, the simulation avatar predicted high BCL2 levels. The combination of BEZ235
(PI3K/mTOR inhibitor) and ABT199 (BCL2 mimetic) was predicted to result in a synergistic reduction in proliferation and viability endpoints.
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Figure 4 MM patient 2 profile schematic. (A) The key signaling pathways and crosstalk relevant for MM patient 1 are presented. This profile
exhibits a chromosome 11:14 translocation, losses in chromosomes X and 9, amplification of CCND1 and a knockdown of tumor suppressors
RXRA, TGFBR1, TJP2 and TSC1. The combination of trametinib (ERK inhibitor) and sirolimus (mTOR1 inhibitor) were predicted to demonstrate
optimal efficacy. The predictive (B) vs. experimental (C) results regarding the impact of sirolimus and trametinib individually and in combination
on relative cell growth. (D) Western blot of non-treated (NT), trametinib (T), sirolimus (S) and combination (S/T) for the biomarker cyclin D1 and
CDKN1A. Actin serves as a loading control.
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BRAF, CUX1, EZH2, MET, NRF1, SMO, CUL1 and
RHEB genes was noted from the aCGH and SKY
profiling of the patient tumor. This patient profile
also contained the commonly reported MM
translocation t(11; 14)(q13; q32) that results in an
amplification of the following genes: AIP, PDEA2,
TCL1A, RCE1, CCND1, MAP4K2, MAP3K11,
AKT1, YY1, FOSL1, FGF19 and IL18BP. The
deletion and amplification of the above genes was
input to create the patient simulation avatar. Loss of
CUL1 due to deletion of chromosome 7q36.1 region
and the gain of CCND1 as a result of gain of
chromosome 11q13 region were identified as key
patient characteristics.
b. Design of individualized therapy
The predictive results indicate bortezomib resistance
in this profile. Based on the dose response studies,
IC15 and IC30 viability was determined for the
responsive drugs, which were combined at these
concentrations with bortezomib in an exhaustive
combination simulation experiment. We then
shortlisted combinations that exhibited synergistic
efficacy on the tumor endpoints by reducing viability
and proliferation in combination with bortezomib.
The combination of bortezomib with BEZ235
(PI3K/mTOR inhibitor) aligned the best with the
driver pathways in the patient profile and was
prospectively validated ex vivo in patient-derived
tumor cells.
c. Ex vivo validation
A bortezomib dose response was performed
individually and in combination with 1 and 5 μM
BEZ235 (Figure 5B). Consistent with the predictions,
this profile was resistant to increasing doses of
bortezomib, and this resistance was overcome with
the addition of BEZ235 (Figure 5A). Predictions of
increased NFkβ in the basal profile with bortezomib
(Figure 5C) were validated in the ex vivo sample
(Figure 5E), and the combination revealed an
enhanced decrease in NFkβ and a synergistic
increase in the apoptotic marker cleaved PARP1
(Figure 5D and E).
Figure 5 MM patient 3 predictive vs. experimental results. Predictive (A) vs. experimental (B) results regarding the effect of bortezomib and
BEZ235 alone and in combination on cell proliferation in MM patient 3. Increasing doses of bortezomib are plotted on the x-axis, represented as
fractions of concentration C (~70% target inhibition) for the predictive plot (A) and as micromolar concentrations of the drug in the experimental
plot (B). The % change in proliferation from untreated baseline is plotted on the y-axis. Predictive results for the effect of bortezomib and BEZ235
alone and in combination on NFkβ (C) and cleaved-PARP1 (D), with the % change in the biomarker from untreated baseline plotted on the
y-axis. (E) Western blot of non-treated (NT), bortezomib (BTZ) alone, BEZ235 (BEZ) alone and the combination (BTZ/BEZ) on the biomarkers NFkβ
and cleaved PARP1. Actin serves as the loading control.
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d. Discussion
The key characteristics of the patient simulation
avatar included CUL1, CAV1 deletion, translocation
of chromosome 11/14 and resulting amplification of
CCND1 and AKT1 (Figure 6). CUL1 is the ubiquitin
E3 ligase that facilitates targeting of many proteins,
including Notch, CTNNB1, and NFkβIA, for
proteasomal degradation [26]. A CUL1 deletion
indicates a defect in this targeting and therefore
protein accumulation. Bortezomib is an inhibitor of
the proteasome, and the therapeutic effect of
proteasome inhibition is mediated via accumulation
of the tumor suppressor proteins, such as cell cycle
inhibitors that aid in controlling increased tumor
cell proliferation [27]. In this profile, an
accumulation of the tumor promoter genes is
expected based on CUL1 and CAV1 deletions, and
further inhibition of the proteasome with
bortezomib is predicted to further increase the
expression of these tumor promoters. Thus, no
reduction in the tumor endpoints is expected,
resulting in drug resistance. AKT1 is overexpressed
due to 11/14 chromosome translocation. The
PI3K-AKT pathway is more dominant than the ERK
pathway in this profile. The individualized therapy
was designed to target the PI3K/mTOR axis to
overcome bortezomib resistance. The addition of the
PI3K/mTOR inhibitor BEZ235 potentially causes
reduced AKT expression and impacts global
translation machinery via mTOR inhibition. This
allows bortezomib–mediated proteasome inhibition
to become more effective by tilting the balance
towards the tumor suppressor accumulation over
the effect of oncogene accumulation, thereby making
this combination effective in this profile as
confirmed by the ex vivo studies on the patient cells.
Case study 4
a. Patient genomic characteristics and creation of
patient simulation avatar
Input for patient profile creation included karyotype
data and FISH analysis. Based on the cytogenetics
and clinical genomics report, patient aberrations
included trisomy of CCND1 and deletion of P53
along with single copy losses in different arms of
chromosomes 1, 6, 8, 12, 13, 14, 16, 17 and 22 as
well as gains in different arms and regions of
chromosomes X, 1, 4, 7, 9, 17, 3, 5, 11, 15, and 19,
indicating the presence of hyperdiploid clones. Using
this information, 897 gene perturbations were used
to model this patient simulation avatar.
Figure 6 MM patient 3 profile schematic. The key signaling pathways and crosstalk relevant for MM patient 3 are presented. This profile
contained multiple aberrations, including a chromosome 11:14 translocation. The profile exhibited a CUL1 deletion and increased CTNNB1; the
patient was clinically resistant to bortezomib. The profile also contained an amplification of RHEB1, implicating activation of the mTOR pathway.
The PI3K/mTOR inhibitor BEZ235 in combination with bortezomib was predicted to be effective in this patient.
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b. Design of individualized therapy
The key characteristics of this profile are presented
as a network schematic (Figure 7A). Simulation
predicted increased beta-catenin (CTNNB1) activity
with increased hedgehog and NOTCH pathways.
The hedgehog pathway was amplified due to high
CNV of SHH, SMO and ADBRK1. The profile
exhibited high CNV of DLL4, FURIN and NOTCH1,
thereby increasing NOTCH signaling. Significant
activation of STAT3 and STAT5 were noted in the
simulation avatar due to amplification of the IL6
pathway as well as JAK2 and JAK3. High CNV of
MET, IGFR and FGFR converged at the ERK and
AKT signaling loops. Along with deletion of P53, this
profile exhibited amplification of many anti-apoptotic
genes including, survivin, MCL1 and XIAP. High
throughput simulation-based testing of the drug
library on the patient simulation avatar identified
the JAK inhibitor tofacitinib, a drug approved for
rheumatoid arthritis, to be effective for this profile.
Figure 7 Data for MM patient 4. (A) Rationale for MM patient 4 patient characteristics and predicted effects on the network. This profile
exhibited CCND1 trisomy, P53 deletion and extensive aberrations and hyperdiploid clones. The simulation avatar exhibited significant activation
of the ERK, AKT and JAK-STAT signaling pathways. The JAK inhibitor tofacitinib, represented in the red box, was predicted to be effective in this
profile. Predictive (B) vs. experimental (C) results regarding the effect of tofacitinib on cell proliferation in MM patient 4. (D) Western blot of
non-treated (NT) and Tofacitinib (Tofa)-treated cells. The biomarker cleaved PARP was assessed. Actin serves as a loading control.
Doudican et al. Journal of Translational Medicine  (2015) 13:43 Page 11 of 14
c. Ex vivo validation
Figure 7B and C demonstrate a tight correlation
between the predictive and experimental results.
An approximate 30% reduction in cell growth
was noted upon treatment with 5 μM tofacitinib.
A similar trend is noted in the predictive plot.
Furthermore, treatment with 5 μM tofacitinib
induces PARP cleavage.
d. Discussion
This profile exhibited a large number of aberrations,
many of which appeared to be significant drivers
based on their contributions in other cancers,
including the growth factors MET, IGFR, FGFR and
Hedgehog and NOTCH signaling pathways.
However, simulation analysis shortlisted the JAK
inhibitor for this profile due to the significant
activation of STAT3 and STAT5 in the patient
simulation avatar. This was attributed to the high
CNV of the IL6 receptor, the amplification of IL6
pathway and high CNV of JAK2 and JAK3, which
are downstream the IL6 pathway. Thus, this
pathway was predicted to be a key driver in this
profile. A combination of the JAK inhibitor with
other modulators that target the other highly up-
regulated pathway could possibly exhibit increased
efficacy; however, due to the lack of availability of
additional patient cells, we could only validate and
confirm the efficacy of tofacitinib and the dominance
of the JAK-STAT signaling in this profile.
Conclusion
Drug resistance and myeloma relapse are commonly ob-
served in MM patients [2]. Using clinical trials to develop
alternative drug therapies for MM patients (resistant to a
particular therapy) typically requires several years of
validation and risk assessment [28]. We developed and
validated a predictive patient specific simulation model
that can design therapeutics in a shorter time period with
potentially increased success.
Rather than the conventional one gene mutation in-
fluencing the sensitivity of a drug approach (i.e., recom-
mendation of use of an EGFR inhibitor in an EGFR
over-expressed or mutant profile), our personalized ther-
apy regime is based on the impact of drugs on the patient’s
signaling networks driven by multiple chromosomal
aberrations. Our personalized therapy design requires
simulation-based analyses of the dominance of key bio-
markers, pathways and convergence points within the
patient network.
The predictive simulation approach comprehensively
models signal transduction, epigenetic regulation, regula-
tion of protein homeostasis (proteasome and autophagy),
metabolic pathways and other regulations representing
all cancer phenotypes with ongoing enhancements. The
technology has the ability to predict clinical outcomes
and enables the design of personalized therapeutic
assets and novel biomarkers for stratification of target
patient sub-groups.
The therapeutic strategy uses repurposing of molecu-
larly targeted drug agents from across indications to
shortlist therapeutic combinations. The repurposed drug
agent list includes those that are clinically safe but were
ultimately not approved due to an inability to achieved
efficacy goals, sunset FDA-approved agents for use at
end of patent life and other FDA approved on-patent
and off-patent generic agents. The recycling and reuse of
approved and clinically tested drugs provides a faster
path to clinical translation [29].
The simulation technology and approach is highly dif-
ferentiated from other pathway analysis approaches due
to its simulation capability. The simulation predictions
have been prospectively validated [18]. Novel and non-
obvious predictions have created a pipeline of biomarker
and therapeutic patented assets.
Various limitations to this study should be noted. First,
we are unable to separate potential clones from the pa-
tient sample. Therefore, we are unable to determine whe-
ther each drug in the personalized drug combination is
selectively targeting individual patient clones or acting col-
lectively. Some of the drugs produce weak inhibition (less
than 20% growth inhibition), which may not be clinically
relevant. In addition, CD138+ clones were not selected for
in a number of the cases (Cases 1-3). Thus, the cells used
to validate the predictive findings ex vivo may not be com-
pletely representative of the patient’s tumor cells.
Intra-tumor heterogeneity is a significant issue that
plagues the development of effective treatments. Although
not specifically addresses in this study, intra-tumor het-
erogeneity could be potentially addressed by this system
using profiling data on multiple different clones from the
same patient. Data from these clones could be individually
modeled to identify a treatment option that would be
effective in all clones. In addition, this platform could
also be utilized to explore differential gene expression
at different stages of tumor progression and predict corre-
sponding drug regimens. If profiling information of the
tumor sample at different stages or time points in disease
progression could be obtained, each sample could be mo-
deled individually. By comparatively analyzing avatars
from the various stages, one could obtain insight into
the appearance of new aberrations and changes that
potentially influence disease progression. Treatment
alterations could be made as the disease progresses if
this information was available.
Moreover, future iterations of our platform could pro-
vide enhance predictive data. Currently, the dataset used
to create the patient simulation avatar is based on copy
number variation and mutation data. Proteomics data
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could potentially be used to confirm the differential
expression of proteins in the patient network based on
the genomic profile and would provide increased confi-
dence in the patient avatar predictions. Metabolomics
data set would also provide an additional patient avatar
validation and alignment dataset, thus strengthening the
prediction model. Although we are currently unable to
include this information in our platform, future studies
involve enhancing our platform’s capacity to predict
effective drug combinations based on genetic, proteomic,
and metabolomic data.
One challenge in using this information would in-
volve closely monitoring the side effects of novel drug
combinations. Most of the drugs in the library are cur-
rently marketed with known safety and toxicity profiles
and have been administered for extended durations in
humans. However, the effects of drugs in combination
are unknown. The safety of these combinations could
be assessed in animal models before being administered
in a clinical setting.
The design of personalized therapy based on this ap-
proach has the added advantage of addressing resistance
mechanisms upfront that can occur when therapy is
designed based on presence of single mutations. One
mutation or perturbation does not take into account the
other aberrations that can contribute to resistance. For
example, in case study 3, the presence of a deletion in
CUL1 could be responsible for making the profile less
sensitive to bortezomib. In addition, the presence of
other alterations, such as low CNV of APC or CDH1 or
mutations in the RAF-ERK-AP1 loop that has inherently
high levels of beta-catenin (CTNNB1) in the base pro-
file, could also contribute to rapid development of borte-
zomib resistance in the profile. These potentially useful
clinical insights were obtained via this simulation
approach. Our promising data warrant validation in
future clinical trials to advance the personalized care of
MM patients.
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